弥漫大B细胞淋巴瘤的预后免疫风险评分
基于Gene Expression Omnibus数据库956例弥漫大B细胞淋巴瘤患者数据,利用ESTIMATE和CIBERSORT算法构建由8种非淋巴瘤免疫细胞组成的免疫风险评分。
核心结论
- 免疫风险评分是弥漫大B细胞淋巴瘤患者准确且独立的生存预测指标。
研究设计与样本
- 回顾性队列研究,从Gene Expression Omnibus数据库获取956例连续受试者数据。
- 训练队列为GSE10846(n=305),验证队列为GSE87371(n=206)与GSE117556(n=445)合并。
- 使用ESTIMATE算法推断样本中非淋巴瘤细胞比例,使用CIBERSORT算法计算8种非淋巴瘤免疫细胞并构建免疫风险评分。
主要发现
- 富集分析提示免疫风险评分与免疫相关生物学过程和通路调控基因相关。
临床怎么用
- 可利用免疫风险评分对弥漫大B细胞淋巴瘤患者进行生存风险分层。
- 结合年龄、LDH、淋巴瘤类型、ECOG-PS和利妥昔单抗治疗构建列线图可提高预后预测准确性。
局限性
- 研究为回顾性分析,数据来源于公共数据库。
- 免疫风险评分基于算法推断的免疫细胞比例,非直接检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We constructed a prognostic score for persons with diffuse large B-cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206 and GSE117556 n = 445 combined) cohorts. Proportions of non-lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non-lymphoma immune cells calculated using the CIBERSORT algorithm. Five-year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P < 0·001). HR in the validation cohort was HR = 2·17 (1·47, 3·21; P < 0·001). Enrichment analyses indicated correlations with genes controlling immune-related biological processes and pathways. A nomogram comprised of the immune risk score and most covariates including age, lactate dehydrogenase concentration (LDH), lymphoma-type (germinal centre B cell [GCB] versus non-GCB), Eastern Cooperative Oncology Group performance status (ECOG-PS) and rituximab therapy had a C-statistic of 0·76 compared with C-statistics of 0·69 and 0·69 for the International Prognostic Index (IPI) and Revised International Prognostic Index (R-IPI). These data indicate the immune risk score is an accurate, independent survival predictor in persons with DLBCL.
引用
- Ma SY, Tian XP, Cai J, et al. A prognostic immune risk score for diffuse large B-cell lymphoma. Br J Haematol. 2021. PMID: 33942291. doi:10.1111/bjh.17478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。